-
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
Rodriguez-Mogeda, C., van Lierop, Z. Y. G. J., van der Pol, S. M. A., Coenen, L., Hogenboom, L., Kamermans, A., Rodriguez, E., van Horssen, J., van Kempen, Z. L. E., Uitdehaag, B. M. J., Teunissen, C. E., Witte, M. E., Killestein, J. & de Vries, H. E., Dec 2023, In: Journal of neuroinflammation. 20, 1, p. 215 215.Research output: Contribution to journal › Article › Academic › peer-review
-
Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis
Toorop, A. A., Hogenboom, L., Bloem, K., Kocyigit, M., Commandeur, N. W. M., Wijnants, A., Lissenberg-Witte, B. I., Strijbis, E. M. M., Uitdehaag, B. M. J., Rispens, T., Killestein, J. & van Kempen, Z. L. E., 1 Jun 2023, In: Journal of Neurology, Neurosurgery and Psychiatry. 94, 6, p. 487-493 7 p., jnnp-2022-330793.Research output: Contribution to journal › Article › Academic › peer-review
-
Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis
the T2B! immunity against SARS-CoV-2 study group & T2B! immunity against SARS-CoV-2 study group, Jan 2023, In: Annals of neurology. 93, 1, p. 103-108 6 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications